How a lipid secreted by cancer tumours stops the immune system from mounting an immune response against it was discovered by T cell researchers.
When lysophosphatidic acid (LPA) binds to killer T cells, it acts almost like an "invisibility cloak," preventing T cells from recognizing and attacking nascent tumours.
Brain Tumor
Brain tumors are the abnormal growth of brain cells that may be benign or metastatic. Brain tumors account for about 2.4% of all the tumor diagnosesandare most challenging due to their critically delicate location.
Advertisement
Senior author Raul Torres, PhD, professor of immunology at National Jewish Health, said that in recent years, several therapeutic medicines have been developed that spur a person's own immune system to fight cancer.
Scientists have known that LPA is secreted by many types of cancer cells, appears to promote the growth and spread of tumor cells, and that immune cells known as CD-8 "killer" T cells have several receptors for LPA. Killer T cells can destroy cancer cells when activated against them.
![Carcinoid Tumors]( "Carcinoid Tumors")
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all carcinoid tumors are associated with the carcinoid syndrome.
Researchers led by Dr. Torres showed that LPA keeps T cells inactivated even after they have "seen" a target, or antigen, on a cancer cell that would normally trigger an immune response.
They identified the LPA5 receptor as the specific receptor responsible for inhibiting the immune response. In cell cultures and in mice LPA prevented signaling within cells, the appearance of molecules associated with T-cell activation, and proliferation of the T cells.
When they transferred T cells lacking the LPA5 receptor into mice with cancer, tumor growth essentially halted.
The study has been published in journal Cancer Immunology Research.
Source: ANI
Carcinoid Tumors
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all carcinoid tumors are associated with the carcinoid syndrome.
Advertisement
Researchers led by Dr. Torres showed that LPA keeps T cells inactivated even after they have "seen" a target, or antigen, on a cancer cell that would normally trigger an immune response.
They identified the LPA5 receptor as the specific receptor responsible for inhibiting the immune response. In cell cultures and in mice LPA prevented signaling within cells, the appearance of molecules associated with T-cell activation, and proliferation of the T cells.
When they transferred T cells lacking the LPA5 receptor into mice with cancer, tumor growth essentially halted.
The study has been published in journal Cancer Immunology Research.
Source: ANI
Pheochromocytoma
Pheochromocytoma is a rare tumor of the adrenal glands that secretes the catecholamines, adrenaline and noradrenaline. Symptoms, diagnosis, treatment of adrenal gland tumor are explained in detail.
Advertisement
 Tumor Markers For Cancer Diagnosis and PrognosisAn ideal tumor marker for a cancer should be specific to that cancer and not generate false positive results. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
